Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients

Nephrol Dial Transplant. 2016 Sep;31(9):1508-14. doi: 10.1093/ndt/gfv414. Epub 2016 Jan 31.

Abstract

Background: Phosphorus control is generally considered to be better in peritoneal dialysis (PD) patients as compared with haemodialysis (HD) patients. Predialysis phosphorus concentrations are misleading as a measure of phosphorus exposure in HD, as these neglect significant dialysis-related fluctuations.

Methods: Parameters of mineral metabolism, including parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23), were determined in 79 HD and 61 PD patients. In PD, phosphorus levels were determined mid-morning. In HD, time-averaged phosphorus concentrations were modelled from measurements before and after the mid-week dialysis session. Weekly renal, dialytic and total phosphorus clearances as well as total mass removal were calculated from urine and dialysate collections.

Results: Time-averaged serum phosphorus concentrations in HD (3.5 ± 1.0 mg/dL) were significantly lower than the mid-morning concentrations in PD (5.0 ± 1.4 mg/dL, P < 0.0001). In contrast, predialysis phosphorus concentrations (4.6 ± 1.4 mg/dL) were not different from PD. PTH and FGF-23 levels were significantly higher in PD. Despite higher residual renal function, total phosphorus clearance was significantly lower in PD (P < 0.0001). Total phosphorus mass removal, conversely, was significantly higher in PD (P < 0.05).

Conclusions: Our data suggest that the time-averaged phosphorus concentrations in patients treated with PD are higher as compared with patients treated with HD. Despite a better preserved renal function, total phosphorus clearance is lower in patients treated with PD. Additional studies are needed to confirm these findings in a population with a different demographic profile and dietary background and to define clinical implications.

Keywords: CKD-MBD; FGF-23; dialysis; hyperphosphataemia; mineral metabolism.

Publication types

  • Clinical Trial
  • Comparative Study
  • Observational Study

MeSH terms

  • Aged
  • Biomarkers / blood*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dialysis Solutions
  • Female
  • Fibroblast Growth Factor-23
  • Humans
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Peritoneal Dialysis*
  • Phosphorus / blood*
  • Renal Dialysis*

Substances

  • Biomarkers
  • Dialysis Solutions
  • FGF23 protein, human
  • Parathyroid Hormone
  • Phosphorus
  • Fibroblast Growth Factor-23